Dacetuzumab
(Anti-human CD40 mAb, human IgG1-Kappa; SGN-40)
Catalog No.: PC-Ab1099Not For Human Use, Lab Use Only.
Dacetuzumab (SGN-40, huS2C6) is a humanized anti-CD40 monoclonal antibody that specifically binds to and works against a molecule called a CD40 receptor. Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. Dacetuzumab demonstrated antitumor activity in relapsed/refractory diffuse large
Dacetuzumab (SGN-40, huS2C6) is a humanized anti-CD40 monoclonal antibody that specifically binds to and works against a molecule called a CD40 receptor. Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. Dacetuzumab demonstrated antitumor activity in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Dacetuzumab induces ADCC and ADCP via interaction with Fc receptors on T cells, NK cells, monocytes, and macrophages.
Physicochemical Properties
M.Wt
Formula
Human IgG1-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
